19 citations
,
August 2019 in “Dermatologic therapy” Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
111 citations
,
June 2015 in “Age and Ageing” Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
January 1988 in “Chemical and Pharmaceutical Bulletin” IND-Ca ointment effectively reduces inflammation with minimal skin irritation.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
1 citations
,
September 2010 in “UEF eRepo (University of Eastern Finland)” Androgen receptors help prostate cancer cells grow and resist drugs.
March 2026 in “Tropical Journal of Natural Product Research” Albizia saponaria bark extract may help treat hair loss.
44 citations
,
October 2009 in “Journal of the American Academy of Dermatology” Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
4 citations
,
January 2023 in “Journal of Human Hypertension” Women experience more side effects and have worse blood pressure control from hypertension treatments than men, despite using different medications.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
June 2026 in “Dermatology and Therapy” In the first 10 months following its FDA approval in June 2023, ritlecitinib was prescribed to a diverse group of patients aged ≥12 years with severe alopecia areata (AA) in the USA. This study analyzed data from 2,562 patients in cohort 1 and 381 in cohort 2, revealing that 62% were prescribed ritlecitinib by dermatologists, 59% were female, and 35% were adolescents. Approximately 24% had severe AA forms like alopecia totalis or universalis, 12% had other autoimmune disorders, 24% had atopic disorders, and 24% had mental health conditions. Before starting ritlecitinib, 27% had no prior AA treatments, while about one-third received systemic immunomodulators or injectable corticosteroids. In cohort 2, 77% experienced ≥50% scalp hair loss. The findings suggest ritlecitinib offers new opportunities for engaging patients in AA care, regardless of their treatment history or comorbidities.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study explores the potential of quercetin and kaempferol, two plant-derived flavonoids, as dual inhibitors of JAK3 kinase and 5-alpha reductase type 2 (5-AR2) for treating androgenetic alopecia (AGA). Using molecular docking simulations, quercetin showed the strongest binding affinity to JAK3 kinase, surpassing the reference drug tofacitinib, while both flavonoids demonstrated moderate binding to 5-AR2, within the inhibitory range for polyphenolic flavonoids. Quercetin's favorable ADMET profile, including suitable skin permeability and safety, highlights its promise for topical application. These findings support further research into these compounds as safer, natural alternatives for AGA management.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
January 2024 in “Faculty of 1000 Research Ltd” Tazarotene gel may be more effective for acne than adapalene gel.
January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
April 2019 in “International research journal of pharmacy” Adiantum capillus extract reduces pain and swelling in animals.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
August 2018 in “Journal of The American Academy of Dermatology” Oral alitretinoin is effective for certain types of chronic hand eczema, with mild side effects.
18 citations
,
January 2013 in “Evidence-based Complementary and Alternative Medicine” Aconiti Lateralis Preparata Radix helps mouse stem cells grow and turn into bone cells faster than usual methods.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
12 citations
,
December 2012 in “Current Drug Targets” The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
4 citations
,
June 2020 in “Processes” Geranium sibiricum may help manage diabetic complications by inhibiting a key enzyme.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
7 citations
,
January 2022 in “Bioengineering” The formulation with oleic acid may be better for treating male pattern baldness.
16 citations
,
January 2013 in “Pediatric Gastroenterology Hepatology & Nutrition” Azathioprine caused side effects in over half of the Korean pediatric inflammatory bowel disease patients, requiring close monitoring.